サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1534411

急性細菌性皮膚・皮膚構造感染症の世界市場：市場規模、シェア、動向分析、機会、予測、2019～2030年

Acute Bacterial Skin and Skin Structure Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type of Infection; By Route of Administration; By Distribution Channel; By Region

出版日
ページ情報
英文 400 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
急性細菌性皮膚・皮膚構造感染症の世界市場：市場規模、シェア、動向分析、機会、予測、2019～2030年
出版日: 2024年07月01日
発行: Blueweave Consulting
ページ情報: 英文 400 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）の市場規模は、CAGRが2.4倍で急拡大し、2030年までに235億米ドルに達すると予測されています。

急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場は、ABSSSIの罹患率の増加、抗生物質耐性、治療オプションの進歩、医療費の増加や啓蒙活動などにより、著しい成長率で繁栄しています。

当レポートでは、2023年の世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）の市場規模を金額ベースで96億5,000万米ドルと推定しました。2024～2030年にかけての予測期間において、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場規模はCAGR 10.55%で拡大し、2030年には234億9,000万米ドルに達するとBlueWeaveは予測しています。世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場は、製薬会社やバイオ医薬品会社による認知度の向上と研究開発活動により、著しい成長を遂げています。これらの感染症を引き起こす一般的な細菌には、化膿レンサ球菌や黄色ブドウ球菌が含まれ、抗MRSA薬は重要な新興概念です。パイプラインの開拓、研究開発費、医薬品の承認が市場を牽引すると予想されます。Melinta Therapeutics社などの主要市場プレーヤーも、リポグリコペプチド系抗生物質KIMYRSAなどの新製品や活動を開始しています。これらの要因は、予測期間中に市場を牽引すると予想されます。

機会 - 診断と治療における技術の進歩

診断ツールや治療方法における最近の技術革新は、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場の状況を一変させています。高度な画像診断技術や迅速な診断テストが早期発見を強化し、迅速な介入と患者の転帰の改善につながっています。さらに、抗生物質耐性株に対応した新規抗生物質や治療法の開発により、これまで満たされていなかった医療ニーズへの対応が進んでいます。このような技術的進歩は、在院日数やヘルスケアコストを削減するだけでなく、市場範囲を世界的に拡大しています。その結果、ABSSSIの世界市場は、医療技術の絶え間ない進歩によって大きく成長する態勢を整えています。

地政学的緊張の高まりが世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場に与える影響

地政学的緊張の激化は、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場に大きな混乱を引き起こしています。特に抗生物質や医療用品のサプライチェーンの混乱は、患者のケアや治療効果を妨げます。政情不安や経済制裁も医薬品の製造や流通に支障をきたし、医薬品不足やコスト増につながります。国際的な協力関係の低下や外交関係の緊張は、研究開発の努力を阻害する可能性があります。

急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場

急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場 - 流通チャネル別

流通チャネル別に見ると、急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場は、病院薬局、小売薬局、オンライン薬局の各セグメントに分けられます。病院薬局セグメントは、複雑な感染症を効果的に管理し、必要な薬剤をタイムリーに提供し、特に即時かつ集中的なケアが必要な病院環境において高度なヘルスケアインフラを提供する能力により、世界のABSSSI市場を独占しています。

競合情勢

世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場は競争が激しいです。同市場の主要企業には、Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V.が挙げられます。これらの企業は、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場における地位をさらに強化するために、研究開発活動への投資の増加、合併・買収、合弁事業、提携、ライセンス契約、新製品・新用量のリリースなど、さまざまな戦略を駆使しています。

本レポートの詳細な分析により、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場の成長可能性、今後の動向、統計に関する情報を提供します。また、総市場規模の予測を促進する要因にも注目しています。当レポートは、世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場の最新技術動向や、意思決定者が健全な戦略的意思決定を行うための産業洞察の提供をお約束します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）の市場分析

  • 産業バリューチェーン分析
  • DROC分析
    • 成長促進要因
      • 抗生物質耐性の蔓延
      • 高齢化社会
      • 侵襲的医療処置の増加
      • ABSSSIの認知度向上
    • 抑制要因
      • 治療費の高騰
      • 有効な抗生物質の入手が限られている
    • 機会
      • 診断と治療における技術的進歩
      • 新興市場に焦点を当てる
    • 課題
      • 抗生物質の不適切な使用と自己投薬
      • 意識と衛生習慣の欠如
  • 技術の進歩/最近の動向
  • 規制の枠組み
  • ポーターのファイブフォース分析

第4章 世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：マーケティング戦略

第5章 世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：地域分析

  • 急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場、地域分析、2023年
  • 急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場、市場の魅力分析、2024-2030年

第6章 急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界市場概要

  • 市場規模と予測、2019～2030年
    • 金額別
  • 市場シェアと予測
    • 感染の種類別
      • 院内感染性ABSSI
      • 市中感染性ABSSI
    • 投与経路別
      • 経口
      • 非経口
      • 話題
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • ラテンアメリカ
      • 中東・アフリカ

第7章 北米の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場

第8章 欧州の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場

第9章 アジア太平洋の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場

第10章 ラテンアメリカの急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場

第11章 中東・アフリカの急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場

第12章 競合情勢

  • 主要プレーヤーとその提供内容のリスト
  • 急性細菌性皮膚・皮膚構造感染症（ABSSSI）の世界企業市場シェア分析、2023年
  • 経営パラメータによる競合ベンチマーキング
  • 主要な戦略的展開（合併、買収、提携など）

第13章 高まる地政学的緊張が世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場に与える影響

第14章 企業プロファイル

  • Pfizer
  • Merck &Co.
  • AbbVie
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline
  • Johnson &Johnson
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi SA
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • その他の主要企業

第15章 主要な戦略的提言

第16章 調査手法

目次
Product Code: BWC24485

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Size Zooming 2.4X at Stellar CAGR to Touch USD 23.5 Billion by 2030

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is flourishing at a significant growth rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising healthcare expenditure and awareness initiatives.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size by value at USD 9.65 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size to expand at a CAGR of 10.55% reaching a value of USD 23.49 billion in 2030. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is growing at a significant rate due to increasing awareness and R&D activities by pharmaceutical and biopharmaceutical companies. Common bacteria causing these infections include Streptococcus pyogenes and Staphylococcus aureus, with anti-MRSA drugs being a crucial emerging concept. Pipeline development, R&D expenditure, and drug approvals are expected to drive the market. Key market players, such as Melinta Therapeutics, are also launching new products and activities, such as KIMYRSA, a lipoglycopeptide antibiotic. These factors are expected to drive the market during the forecast period.

Opportunity - Technological advancements in diagnostics and treatment

Recent innovations in diagnostic tools and treatment modalities are revolutionizing the landscape of Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market. Advanced imaging techniques and rapid diagnostic tests are enhancing early detection, leading to prompt interventions and improved patient outcomes. Moreover, the development of novel antibiotics and therapies tailored to antibiotic-resistant strains is addressing previously unmet medical needs. These technological strides are not only reducing hospital stays and healthcare costs but also expanding the market scope globally. As a result, Global ABSSSI Market is poised for substantial growth driven by continuous advancements in medical technology.

Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Intensifying geopolitical tensions are causing significant disruptions in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. Disruptions in supply chains, particularly for antibiotics and medical supplies, hinder patient care and treatment efficacy. Political instability and economic sanctions can also hinder pharmaceutical manufacturing and distribution, leading to drug shortages and increased costs. Reduced international collaboration and strained diplomatic relations can stifle research and development efforts.

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - By Distribution Channel

Based on distribution channel, Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex infections effectively, provide timely access to necessary medications, and offer advanced healthcare infrastructure, particularly in hospital settings where immediate and intensive care is required.

Competitive Landscape

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is fiercely competitive. Major companies in the market include Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and dose releases to further strengthen their position in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Prevalence of Antibiotic Resistance
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Increase in Invasive Medical Procedures
      • 3.2.1.4. Growing Awareness of ABSSSI
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Treatment
      • 3.2.2.2. Limited Availability of Effective Antibiotics
    • 3.2.3. Opportunities
      • 3.2.3.1. Technological Advancements in Diagnostics and Treatment
      • 3.2.3.2. Focus on Emerging Markets
    • 3.2.4. Challenges
      • 3.2.4.1. Improper Antibiotic Use and Self-Medication
      • 3.2.4.2. Lack of Awareness and Hygiene Practices
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Marketing Strategies

5. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Geographical Analysis

  • 5.1. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Geographical Analysis, 2023
  • 5.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Market Attractiveness Analysis, 2024-2030

6. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Overview

  • 6.1. Market Size & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Infection
      • 6.2.1.1. Hospital-acquired ABSSI
      • 6.2.1.2. Community-acquired ABSSI
    • 6.2.2. By Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. ParentaL
      • 6.2.2.3. Topical
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Infection
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Type of Infection
      • 7.2.4.1.2. By Route of Administration
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Type of Infection
      • 7.2.4.2.2. By Route of Administration
      • 7.2.4.2.3. By Distribution Channel

8. Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Infection
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Type of Infection
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Type of Infection
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Type of Infection
      • 8.2.4.3.2. By Route of Administration
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. France
      • 8.2.4.4.1. By Type of Infection
      • 8.2.4.4.2. By Route of Administration
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Type of Infection
      • 8.2.4.5.2. By Route of Administration
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Type of Infection
      • 8.2.4.6.2. By Route of Administration
      • 8.2.4.6.3. By Distribution Channel
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Type of Infection
      • 8.2.4.7.2. By Route of Administration
      • 8.2.4.7.3. By Distribution Channel
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Type of Infection
      • 8.2.4.8.2. By Route of Administration
      • 8.2.4.8.3. By Distribution Channel
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Type of Infection
      • 8.2.4.9.2. By Route of Administration
      • 8.2.4.9.3. By Distribution Channel

9. Asia Pacific Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Infection
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Type of Infection
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. India
      • 9.2.4.2.1. By Type of Infection
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Type of Infection
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Type of Infection
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Australia & New Zealand
      • 9.2.4.5.1. By Type of Infection
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Type of Infection
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Type of Infection
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Type of Infection
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Type of Infection
      • 9.2.4.9.2. By Route of Administration
      • 9.2.4.9.3. By Distribution Channel
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Type of Infection
      • 9.2.4.10.2. By Route of Administration
      • 9.2.4.10.3. By Distribution Channel

10. Latin America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Infection
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Type of Infection
      • 10.2.4.1.2. By Route of Administration
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Type of Infection
      • 10.2.4.2.2. By Route of Administration
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Type of Infection
      • 10.2.4.3.2. By Route of Administration
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Type of Infection
      • 10.2.4.4.2. By Route of Administration
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Type of Infection
      • 10.2.4.5.2. By Route of Administration
      • 10.2.4.5.3. By Distribution Channel

11. Middle East & Africa Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Million)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type of Infection
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Type of Infection
      • 11.2.4.1.2. By Route of Administration
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Type of Infection
      • 11.2.4.2.2. By Route of Administration
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Type of Infection
      • 11.2.4.3.2. By Route of Administration
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Type of Infection
      • 11.2.4.4.2. By Route of Administration
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Type of Infection
      • 11.2.4.5.2. By Route of Administration
      • 11.2.4.5.3. By Distribution Channel
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Type of Infection
      • 11.2.4.6.2. By Route of Administration
      • 11.2.4.6.3. By Distribution Channel
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Type of Infection
      • 11.2.4.7.2. By Route of Administration
      • 11.2.4.7.3. By Distribution Channel
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Type of Infection
      • 11.2.4.8.2. By Route of Administration
      • 11.2.4.8.3. By Distribution Channel

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Company Market Share Analysis, 2023
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

13. Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 14.1. Pfizer
  • 14.2. Merck & Co.
  • 14.3. AbbVie
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. GlaxoSmithKline
  • 14.6. Johnson & Johnson
  • 14.7. Eli Lilly and Company
  • 14.8. Novartis AG
  • 14.9. Sanofi S.A.
  • 14.10. AstraZeneca PLC
  • 14.11. Teva Pharmaceutical Industries Ltd
  • 14.12. Mylan N.V.
  • 14.13. Other Prominent Players

15. Key Strategic Recommendations

16. Research Methodology

  • 16.1. Qualitative Research
    • 16.1.1. Primary & Secondary Research
  • 16.2. Quantitative Research
  • 16.3. Market Breakdown & Data Triangulation
    • 16.3.1. Secondary Research
    • 16.3.2. Primary Research
  • 16.4. Breakdown of Primary Research Respondents, By Region
  • 16.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable